Idiopathic Pulmonary Fibrosis (IPF) Cohort vs Non Idiopathic Pulmonary Fibrosis (IPF) Cohort: Sustained Oxygen Therapy Use Within the First 12 Months of Follow-up
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.722 | 0.698 | 0.746 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.47 | 0.46 | 0.479 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.253 | 0.226 | 0.278 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.54 | 1.48 | 1.6 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 2.94 | 2.59 | 3.33 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Idiopathic Pulmonary Fibrosis (IPF) Cohort than on Non Idiopathic Pulmonary Fibrosis (IPF) Cohort | 3.96 | 3.6 | 4.42 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Idiopathic Pulmonary Fibrosis (IPF) Cohort | Patients aged ≥ 18 years with newly diagnosed fibrosing interstitial lung disease (ILD) during the patient identification period with ≥2 fibrosing ILD diagnoses, continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date (pre-ILD baseline period) and ≥2 medical claims with diagnosis for idiopathic pulmonary fibrosis (IPF) in any position during the study period. | 967 | 1,339 | OG000 | ClinicalTrials.gov |
| Group 2 | Non Idiopathic Pulmonary Fibrosis (IPF) Cohort | Patients aged ≥ 18 years with newly diagnosed fibrosing interstitial lung disease (ILD) during the patient identification period with ≥2 fibrosing ILD diagnoses, continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date (pre-ILD baseline period) and no claims with diagnosis for idiopathic pulmonary fibrosis (IPF) in any position during the study period. | 4,973 | 10,592 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Sustained Oxygen Therapy Use Within the First 12 Months of Follow-up | ClinicalTrials.gov |
| Description | The number of participants with ≥ 11 claims for oxygen therapy within 12 months of initiating oxygen therapy is reported.~Using claims, sustained oxygen therapy use was defined among patients with at least 12 months of follow-up after the index date (oxygen initiation date), as a binary variable for the presence of ≥11 claims for oxygen therapy in a 12-month period. | ClinicalTrials.gov |
| Time frame | Up to month 12 of follow-up, in patient identification period from 01 October 2016 through 30 June 2022. | ClinicalTrials.gov |
| Population | Population AIM 1 include patients newly diagnosed with fibrosing ILD during the patient identification period and met all the eligibility criteria.~Population AIM 1 in this endpoint restricted to patients with sustained oxygen therapy use within 12 months of initiating oxygen therapy patients and with ≥ 11 claims for oxygen therapy within 12 months of initiating oxygen therapy. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease | ClinicalTrials.gov |
| NCT number | NCT05957198 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Lung Diseases, Interstitial | ClinicalTrials.gov |
| Interventions | ClinicalTrials.gov | |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Results first posted | 2024-11-21 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05957198?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.